Nilutamide: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Prostate Cancer

Drugs & Aging

Volumn 3, Issue 1, 1993, Pages 9-25

  Harris, Martin G ^a   Coleman, Stephen G ^a   Faulds, Diana ^a   Chrisp, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; NILUTAMIDE;

AGED; HUMAN; MALE; PROSTATE TUMOR; REVIEW;

AGED; ANTINEOPLASTIC AGENTS; HUMAN; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS;

EID: 0027356895     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199303010-00002     Document Type: Article

References (69)

1. Clinical study of RU23908 (nilutamide) in prostatic cancer
2. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (Nilutamide)-induced hypersensitivity pneumonitis
3. Prognostic significance of prostate specific antigen in endocrine treatment for prostate cancer
4. Inhibition of rat testicular 17α-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro
5. Inhibitory effects of nilutamide, a new androgen receptor antagonist, on mouse and human liver cytochrome P-450
6. Total androgen ablation: Canadian experience
7. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer
8. Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen
9. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, Nilutamide
10. Efficacy of the combination of Anandron (nilutamide) with orchidectomy in metastatic prostatic cancer. A metaanalysis of seven randomised double-blind trials (1191 patients)
11. Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate
12. Anandron (RU 23908) in metastatic prostate cancer: Preliminary results of a multicentric Italian study
13. Anandron (RU 23908) associated to surgical castration in previously untreated Stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo
14. Flutamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in advanced prostatic cancer
15. Effectiveness of antiandrogens in the rat
16. Pharmacokinetics and metabolism of nilutamide in the isolated rat lung
17. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders
18. Treatment of Stage D2 prostate cancer with lcuprolidc and Anandron compared to leuprolide and placebo
19. Pharmacokinetics and metabolism of nilutamide
20. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate
21. Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate
22. Effect of a nonsteroidal antiandrogen, anandron, on the reproductive system and fertility in male rats
23. Prostate specific antigen and prostatic phosphatase for monitoring therapy of carcinoma of the prostate
24. Redox cycling of the antiandrogen nilutamide leads to oxidtive stress in isolated hepatocytes
25. Plasma hormone levels before and after orchiectomy in prostate cancer patients and action of a non-steroid antiandrogen anandron
26. GnRH agonists and antagonists: current clinical status
27. GnRH and its analogues: current therapeutic applications and new prospects
28. Pharmacology and antiandrogens and value of combining androgen suppression with antiandrogen therapy
29. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report
30. Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen
31. Acute hepatitis related to the use of nilutamide (Anadron®)
32. Ocular toxicity of anandron in patients treated for prostatic cancer
33. Studies on prostatic cancer I. The effect of castration, estrogen and of androgen injections on serum phosphatase in metastatic carcinoma of the prostate
34. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic canccr in a multinational double-blind randomized trial
35. Toxicité pulmonaire du nilutaminc (Anadron®). Bilan coopératif des centres français dc pharmacovigilance
36. Die Therapie des metastasierten Prostatakarzinoms durch Orchicktomic plus Anandron versus Orchicktomic plus Placebo
37. Prevention of the transient adverse effects of a gonadotrophin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)
38. Traitement anti-androgénique combiné dans l’adénocarcinome de la prostate: première application d’un nouveau principe thérapeutique efficace dans le cancer hormono-dépendant
39. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens
40. Medical castration with LHRH agonists and the need for combined treatment with an antiandrogen in prostate cancer. Horm
41. Combined long-term treatment with an LHRH agonist and a prue antiandrogen blocks androgenic influence in the rat
42. Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. New England Journal of Medicine 311: 1281–1286, 1984
43. Pharmacological and clinical studies of the antiandrogen anandron
44. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer
45. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist Buserelin in the rat
46. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma
47. The proliferative effect of ‘anti-androgens’ on the androgen-sensitive human prostate tumor cell line LNCaP
48. A randomized double-blind study evaluating Anandron associated with orchiectomy in Stage D prostate cancer
49. 2 prostate cancer patients receiving buserelin: results on 49 cases from a multicentre study
50. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer
51. Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate
52. Nilutamide pneumonitis: a report on 8 patients
53. Nilutamide-induced pneumopathy: 3 cases
54. Merits and considerations in the use of anti-androgen
55. Antiandrogens in combination with LH-RH agonists in prostate cancer
56. Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues
57. The pure antiandrogen RU 23908 (Anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review
58. Pharmacology and Clinical studies with RU 23908 (Anandron). In EORTC genitourinary group monograph 2, Part A
59. Treatment of stage IV carcinoma of the prostate
60. Effects of massive ingestion of nitulamide
61. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion
62. Pulmonary complications of hormone treatment in prostate carcinoma
63. Effects of steroidal and nonsteroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor
64. Pharmacological activity of four metabolites of Anandron®. Abstract
65. The kinetics of antiandrogens in humans
66. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation
67. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens